Fakultas Kedokteran Universitas Andalas 44

DAFTAR PUSTAKA

1. Saygin C, Carraway HE. Review : Emerging therapies for acute myeloid

leukemia. Journal of Hematology and Oncology.2017; 10(93): 1-12.

2. Enright H, Browne P. Understanding acute myeloid leukaemia. Irish Cancer

Society. 2016: 15-16.

3. Sukardja DG. Onkologi klinik. Edisi 2. Surabaya : Airlangga University

Press. 2000.

4. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK,

dkk. Diagnosis and management of acute myeloid leukemia in adults :

recommendations from an international expert, on behalf of the European

LeukemiaNet. Blood. 2010; 11: 453-74.

5. NCCN Clinical Practice Guidlines in Oncology (NCCN Guidlines) : Acute

Myeloid Leukemia version. 2. National Comprehensive Cancer Network.

2014.

6. NCCN Clinical Practice Guidlines in Oncology (NCCN Guidlines) : Acute

Myeloid Leukemia version. 3. National Comprehensive Cancer Network.

2017.

7. Schlenk RF. Review Articles : Post-remission therapy for acute myeloid

leukemia. Germany: Departement of Internal Medicine III, University

Hospital Ulm. Hematologica. 2014; 99(11): 1663-1668.

8. Klco JM, Miller CA, Griffith M, dkk. Association between mutation

clearance after induction therapy and outcomes in acute myeloid leukemia.

JAMA. 2015; 314(8): 811-822.

9. Rassi FE, Arellano M. Update on optimal management on acute myeloid

leukemia. Clinical Medicine Insights : Oncology. 2013; 7: 181-197.

10. Rashidi A, Walter RB, Tallman MS, Appelbaum FR, Dipierso JF.

Maintenance therapy in acute myeloid leukemia : an evidence-based review

of randomize trials. Blood. 2016; 128(6): 763-773.

11. Sjakti HA, Gatot D, Windiastuti E. Hasil pengobatan leukemia mieloblastik

akut pada anak. Sari Pediatri. 2012; 14(1).

Fakultas Kedokteran Universitas Andalas 45

12. Instalasi Rekam Medik RSUP Dr. M Djamil Padang. Pasien leukemia

mieloblastik akut tahun 2015-2017. Rekam Medik RSUP Dr. M Djamil

Padang

13. Dorland WAN. Kamus saku kedokteran dorland. Edisi ke 28. Jakarta:Buku

Kedokteran EGC; 2014: 1194.

14. Rofinda ZD. Kelainan hemostasis pada leukemia. Jurnal Kesehatan Andalas.

2012; 1(2): 68-72.

15. Yuliana. Perkembangan terapi leukemia mieloid akut. CDK-250.2017; 44(3):

216-220.

16. Leukemia Foundation. Acute myeloid leukemia : a guide for patients and

families. 2015.

17. Arismendy JP, Arroyave JC, Rothlisberger S. Review : molecular biomarker

in acute myeloid leukemia. Blood Review. 2017; 31; 63-76.

18. WHO.(2012).GLOBOCAN 2012 : Estimated cancer incidence, mortality, and

prevalence worldwide in 2012. www.globocan.iarc.fr - Diakses 25 Agustus

2017.

19. American Cancer Society. (2017). What are the key statistics about acute

myeloid leukemia. American Cancer Society.

http://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.ht

ml - Diakses 25 Agustus 2017.

20. American Cancer Society. (2017). Cancer facts and figures 2017.

http://www.cancer.org/acs/groups/content/@editorial/documents/document/a

cspc-048738.pdf. - Diakses 25 Agustus 2017.

21. Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. 2013.

22. Kouchkovsky ID, Abdul-Hay M. Review acute myeloid leukemia : a

comprehensive review 2016 update. Blood Cancer Journal. 2016; e441(6):

4-1.

23. Wetzler M, Byrd JC, Bloomfield CD. Acute and chronic myeloid leukemia.

In : Longo DL, editor. Harrison’s Hematology and Oncology. 3rd

ed. New

York : McGraw-Hill; 2016: 171-166.

Fakultas Kedokteran Universitas Andalas 46

24. Cortes EJJ, Ravandi F, O’Brien S, Kantarjian H. Targeted therapies in

hematology and their impact on patient care : chronic and acute myeloid

leukemia. Semin Hematol. National Institute of Health. 2013; 50(4): 271-283.

25. Stein EM, Tallman MS. Remission induction in acute myeloid leukemia.

International Journal of Hematology. 2012; 96(2): 164-170.

26. Hoffbrand AV, Moss PAH, Sandra F, editors. Kapita Selekta Hematologi.

Edisi ke-6. Jakarta : EGC ; 2013: 150-166.

27. Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. 13th

ed. New York : McGraw-Hill; 2014.

28. Seiter K, Talavera F. (2017). Acute myelogenous leukemia.

http://emedicine.medscape.com/article/197802-treatment Diakses tanggal 19

Oktober 2017.

29. Tholl F, Schelnk RF, Heuser M, Ganser A. How i treat refractory and early

relapse acute myeloid leukemia. Blood. 2015; 126(3): 319.

30. Eastern Cooperative Oncology Group ;ECOGperformance

status. http://ecog-acrin.org/resources/ecog-performance-status - Diakses 4

November 2017.

31. Crooks V, Waller S, dkk. The use of the karnofsky permorfance scale in

determining outcomes and risk in geriatric outpatients. 1991; 46: 139-144.

32. Almeida AM, Ramos F. Acute myeloid leukemia in older adults. Leukemia

Reseacrch Reports. 2015: 1-7.

33. Ramos F, Thepot S, Pleyer L, dkk. Azaticidine frontline therapy for unfit

acute myeloid leukemia patients : clinical use and outcome prediction.

Leukemia Research. 2015; 39(3): 296-306.

34. Walter RB, Estey EH. Consice Review : Management of older or unfit

patients with acute myeloid leukemia. Leukemia. 2015; 29: 770-775.

35. Walter RB, Taylor RL, Gardner KM, Dorcy KS, Vaughn JE, Estey EH.

Outpatient management following intensive induction or salvage

chemotherapy for acute myeloid leukemia. Clinical Advances Hematology

and Oncology Journal. 2013; 11(9): 571-577.

Fakultas Kedokteran Universitas Andalas 47

36. Kurnianda J. Leukemia mieloblastik akut. Dalam : Sudoyo AW, Setiyohadi

B, Alwi I, Simadibrata M, Setiati S, editors. Buku Ajar Ilmu Penykit Dalam

Jilid 2. Edisi 6. 2015. Jakarta : Balai Penerbit FK UI; 2671-2677.

37. Rasjidi I. Buku ajar onkologi klinis. Edisi 2. Surabaya : Airlangga University

Press. 2000.

38. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy : principles

and practices. 4th

edition. New York : McGraw-Hill; 2006.

39. Yudhani, RD. Continuing professional development : farmakogenomik dan

terapi kanker. CDK-217. 2014; 41(6): 412-415.

40. American Cancer Society. (2016). Treating acute myeloid leukemia : general

treatment information about acute myeloid leukemia.

41. Dohner H, Estey H, Grimwade D, et al. Diagnosis and management of AML

in adults: 2017 ELN recommendations from international expert panel.

Blood. 2017; 129(4): 424-440.

42. Simajorang C. Perbedaan ketahanan hidup 5 tahun pasien leukemia

limfoblastik akut dan leukemia mieloblastik akut di Rumah Sakit Kanker

Dharmais Jakarta tahun 1997-2008 (dissertation). Jakarta : Universitas

Indonesia; 2012.

43. Arber DA, Orazi A, Hassirjian R, et al. The 2016 revision to The World

Health Organization classification of myeloid neoplasm and acute leukemia.

Blood. 2016; 127(20): 2391-2405.

44. Walter RB, Kantarjian Mh, et al. Effects of complete remission and responses

less than complete remission on survival in acute myeloid leukemia: a

combined eastern cooperative oncology group, southwest oncology group,

and M.D Anderson cancer study. 2010; 28(10): 1766-1771.

45. Yu MG, Zheng HY. Acute myeloid leukemia : advancements in diagnosis

and treatment. Chinese Medical Journal. 2017; 130(2): 211-216.

46. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predict survival

for older adults receiving induction chemotherapy for acute myelogenous

leukemia. Blood. 2013; 121(21): 4287-4294.

47. Medeiros BC, Hoang SS, Hurst D, Hoang KQ, Momin F, Reyes C. Big data

analysis of treatment patterns and outcomes among elderly acute myeloid

leukemia patients in The United States. Ann Hematol. 2015; 94: 1127-1138.

Fakultas Kedokteran Universitas Andalas 48

48. Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy

in patients with acute myeloid leukemia arising from myelodysplastic

syndrome. Moffiltt Cancer. 2011: 1463-1469.

49. Chen CC, Yang CF, Yang MH, et al. Pretreatment prognostic factors and

treatment outcomes in elderly patients with de novo acute myeloid leukemia.

Annals of Oncology. 2005; 16: 1366-1373.

50. Nurbaety B, Perwitasari DA, Andalusia R. Penggunaan antibiotik pada pasien

leukemia akut dewasa dengan febrile neutropeniasetelah pemberian

kemoterapi agresif di RS Kanker Dharmais Jakarta. Media Farmasi. 2014;

11(2): 179-188.

51. Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette

smoking and risk of acute myeloid leukemia : an updated meta-analysis of

epidemiological studies. American Journal of Hematology 2014; 89(8):

125-132.

52. Maurillo L, Buccisano F, Principe MI, et al. Treatment of acute myeloid

leukemia with 20-30% bone marrow blasts. Mediterranean Journal of

Hematology and Infectious Disease. 2013; 5(1)

53. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and

chemotherapy dose response in acute myeloid leukemia : astudy by german

acute myeloid leukemia cooperative group. American Society of Clinical

Oncology. 2009; 27(1): 61-68.

54. Vey N, Coso D, Bardou VD, et al. The benefit of induction in patients age ≥

75 years. American Cancer Society. 2004; 101(2): 325-330.

55. Tasaki T, Yamauchi T, Matsuda Y, et al. The response to induction therapy is

crusial for the treatment outcomes of elderly patients with acute myeloid

leukemia: single institusion experience. Anticancer Research. 2014; 34: 5631-

56. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson M, Clark

RE. Attempts to improve treatment outcomes in acute myeloid leukemia in

older patients: the results of the Uninted Kingdom medical research council

AML 11 trials. Blood. 2001; 98(5): 1302-1309.

57. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction

chemotherapy for older patients with acute myeloid leukemia is not improve

with mitoxantrone and etoposide vompared to cytarabine and daunorubicin : a

Shouthwest oncology group study. Blood. 2002; 100(12): 3869-3876.

Fakultas Kedokteran Universitas Andalas 49

58. Baz R, Rodriguez C, Fu AZ, et al. Impact of remission induction

chemotherapy on survival in older adults with acute myeloid leukemia.

American Cancer Society. 2007; 110(8): 1752-1758.

59. Appelbhaum FR, Gundacker H, Head DR, et al. Age and acute myeloid

leukemia. Blood. 2006; 107(9): 3481-3485.

60. Deschler B, Lubbert M. Acute myeloid leukemia : epidemiology and

etiology. Cancer. 2006; 107(9): 2009-2105.

61. Amin Hm, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce FA, dkk. Having a

higher blast percentage in circulation than bone marrow: clinical implications

in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.

Leukemia. 2005; 19: 1567-1572.

62. Hasserjia RP, Campigotto F, Klepeis V, Fu Bin, Wang SA, Byeso-Ramos C,

dkk. De novo acute myeloid leukemia with 20-29% blast is less aggressive

than acute myeloid leukemia with ≥30% blasts in older adults : a bone

marrow pathology group study. American Jurnal of Hematology. 2014;

89(11): 193-198.

63. Brandwein JM, Gupta V, Schuh AC, et al. Predictors of response to

reinduction chemotherapy for patients with acute myeloid leukemia who do

not achieve complete remission with frontline induction therapy. American

Journal of Hematology. 2007: 54-57.

64. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older

patients with acute myeloid leukemia. Cancer. 2013: 2720-2726.

65. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults : incidence

and treatment. Journal of National Cancer Institute. 1999; 91(19): 1616-1630.

66. Porcu P, Cripe LD, Bhatia S. Hiperleukocytic leukemia and leukostasis : a

review of pathophysiology, clinical presentation and management. Leuk

Lymphoma. 2000; 39(2): 1-18.

67. Ma E, Bonthapally V, Chawla A, et al. An Evaluation of treatment patterns

and outcomes in elderly patients newly diagnosed with acute myeloid

leukemia. Clnical Lymphoma, Myeloma, and Leukemia. 2016; 16(11):

625-635.

68. Zhang Q, Dai K, Bi L, et al. Pretreatment platelet count predicts survival

outcome of patients with de novo non-M3 acute myeloid leukemia. PeerJ.

2017; 39: 1-13.

Fakultas Kedokteran Universitas Andalas 50

69. Yoon JH, Cho BS, Kim HJ, et al. Outcomes of elderly de novo acute myeloid

leukemia treated by a risk-adapted approach based on age, comorbidity, and

perfomace status. American Journal of Hematology. 2013; 88: 1074-1081.

70. Wang ES. Treating acute myeloid leukemia in older adults. American Society

of Hematology. 2014: 14-18.

71. Grimwade D, Walker H, Harrison G. Predictive value of hierarchical

cytogenetic classification in older adults with acute myeloid leukemia. Blood.

2001; 98(5): 1312-1320.